Table 3.
Comparison of key study characteristics.
| Citations | Sponsor | Stent device (manufacturer) | Stent location | Stent duration* | Steroid** | Post-operative treatment*** | Study Groups | Maximum Follow-up |
|---|---|---|---|---|---|---|---|---|
| Murr 201125 | Intersect ENT | Unspecified (Intersect ENT) | ethmoid sinus cavity | 30 days (bioabsorbed) | 370μg mometasone furoate | 14-day ABX | SES, control (intrapatient) | 2 Months |
| Marple 201226 | Intersect ENT | Propel (Intersect ENT) | ethmoid sinus cavity | 30 days (bioabsorbed) | 370μg mometasone furoate | 14-day ABX | SES, control (intrapatient) | 3 Months |
| Forwith 201618 | Intersect ENT | Unspecified (Intersect ENT) | ethmoid sinus cavity | 60 days (removed) | 370μg mometasone furoate | Daily steroid nasal spray | SES, control | 3 Months |
| Smith 201627 | Intersect ENT | Propel Mini (Intersect ENT) | frontal sinus ostia | 21 days (removed) | 370μg mometasone furoate | 10-day ABX | SES, control (intrapatient) | 3 Months |
| Businco 201616 | - | Relieva Stratus MicroFlow Spacer (Acclarent) | ethmoid sinus cavity | 28 days (removed) | 12mg triamcinolone acetonide | - | SES, ethmoidectomy | 12 Months |
| Taulu 201717 | - | Relieva Stratus MicroFlow Spacer (Acclarent) | ethmoid sinus cavity | 28 days (removed) | 12mg triamcinolone acetonide | - | SES, nasal spray | 6 Months |
| Adriaensen 201715 | BioInspire Technologies, Inc. | SinuBand FP (BioInspire Technologies, Inc.) | ethmoid sinus cavity | Unspecified | 320μg fluticasone propionate | 14-day ABX | SES, nasal pack, control (intrapatient) | 2 Months |
| Luong 201728 | Intersect ENT | Propel Contour (Intersect ENT) | frontal sinus ostia | 21 days (removed) | 370μg mometasone furoate | 10-day ABX | SES, control (intrapatient) | 3 Months |
| Singh 201829 | Intersect ENT | Propel Mini or Contour (Intersect ENT) | frontal sinus ostia | 21 days (removed) | 370μg mometasone furoate | 10-day ABX | SES, control (intrapatient) | 3 Months |
*:
Approximate length of time steroid was administered before stent was either removed or bioabsorbed.
**:
Quantity is given per side.
***:
Treatment mandated for all subjects in study. Other post-operative treatment may or may not have been permitted; see individual studies for details.